Avalo Therapeutics Stock Buy Hold or Sell Recommendation
| AVTX Stock | USD 15.06 0.58 3.71% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Avalo Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Avalo Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Avalo Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.Check out Avalo Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide. In addition, we conduct extensive research on individual companies such as Avalo and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Avalo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Execute Avalo Therapeutics Buy or Sell Advice
The Avalo recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Avalo Therapeutics. Macroaxis does not own or have any residual interests in Avalo Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Avalo Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Avalo Therapeutics Trading Alerts and Improvement Suggestions
| Avalo Therapeutics generated a negative expected return over the last 90 days | |
| Avalo Therapeutics has high historical volatility and very poor performance | |
| Avalo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Avalo Therapeutics currently holds 568 K in liabilities with Debt to Equity (D/E) ratio of 5.62, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Avalo Therapeutics has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Avalo Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 441 K. Net Loss for the year was (35.13 M) with loss before overhead, payroll, taxes, and interest of (31.91 M). | |
| Avalo Therapeutics currently holds about 11.25 M in cash with (49.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2. | |
| Avalo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of Avalo Therapeutics shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Avalo Therapeutics Gets Buy Rating Reiteration from HC Wainwright AVTX Stock News - GuruFocus |
Avalo Therapeutics Returns Distribution Density
The distribution of Avalo Therapeutics' historical returns is an attempt to chart the uncertainty of Avalo Therapeutics' future price movements. The chart of the probability distribution of Avalo Therapeutics daily returns describes the distribution of returns around its average expected value. We use Avalo Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Avalo Therapeutics returns is essential to provide solid investment advice for Avalo Therapeutics.
| Mean Return | 0.23 | Value At Risk | -6.28 | Potential Upside | 10.71 | Standard Deviation | 4.98 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Avalo Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Avalo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Avalo Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Avalo Therapeutics back and forth among themselves.
| Shares | Blackrock Inc | 2025-06-30 | 155.9 K | Velan Capital Investment Management Lp | 2025-06-30 | 155 K | Perceptive Advisors Llc | 2025-06-30 | 139.7 K | Geode Capital Management, Llc | 2025-06-30 | 110.5 K | Adar1 Capital Management Llc | 2025-06-30 | 104.7 K | Ubs Group Ag | 2025-06-30 | 83.7 K | Sio Capital Management, Llc | 2025-06-30 | 72.2 K | Ikarian Capital, Llc | 2025-06-30 | 35.3 K | Northern Trust Corp | 2025-06-30 | 22.7 K | Bvf Inc | 2025-06-30 | 1 M | Nantahala Capital Management, Llc | 2025-06-30 | 995 K |
Avalo Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 35.8M | (41.5M) | (5.8M) | 127.1M | 146.2M | 153.5M | |
| Free Cash Flow | (71.0M) | (26.8M) | (30.8M) | (49.1M) | (44.2M) | (41.9M) | |
| Depreciation | 1.7M | 166K | 158K | 169K | 194.4K | 184.6K | |
| Other Non Cash Items | 794K | 2.4M | 6.5M | (15.4M) | (13.8M) | (13.1M) | |
| Capital Expenditures | 262.0K | 63K | 113K | 95K | 158K | 0.0 | |
| Net Income | (84.4M) | (41.7M) | (31.5M) | (35.1M) | (31.6M) | (33.2M) | |
| End Period Cash Flow | 54.9M | 13.3M | 7.5M | 134.7M | 154.9M | 162.6M | |
| Investments | (113K) | (95K) | (133K) | 356K | 320.4K | 304.4K |
Avalo Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Avalo Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Avalo Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Avalo stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.16 | |
β | Beta against Dow Jones | 0.67 | |
σ | Overall volatility | 4.78 | |
Ir | Information ratio | 0.03 |
Avalo Therapeutics Volatility Alert
Avalo Therapeutics exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Avalo Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Avalo Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Avalo Therapeutics Fundamentals Vs Peers
Comparing Avalo Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Avalo Therapeutics' direct or indirect competition across all of the common fundamentals between Avalo Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Avalo Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Avalo Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Avalo Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Avalo Therapeutics to competition |
| Fundamentals | Avalo Therapeutics | Peer Average |
| Return On Equity | -1.75 | -0.31 |
| Return On Asset | -0.37 | -0.14 |
| Operating Margin | (346.32) % | (5.51) % |
| Current Valuation | 178.48 M | 16.62 B |
| Shares Outstanding | 18.51 M | 571.82 M |
| Shares Owned By Insiders | 3.48 % | 10.09 % |
| Shares Owned By Institutions | 85.34 % | 39.21 % |
| Number Of Shares Shorted | 2.57 M | 4.71 M |
| Price To Book | 3.16 X | 9.51 X |
| Price To Sales | 1,508 X | 11.42 X |
| Revenue | 441 K | 9.43 B |
| Gross Profit | (31.91 M) | 27.38 B |
| EBITDA | (68.34 M) | 3.9 B |
| Net Income | (35.13 M) | 570.98 M |
| Cash And Equivalents | 11.25 M | 2.7 B |
| Cash Per Share | 1.20 X | 5.01 X |
| Total Debt | 568 K | 5.32 B |
| Debt To Equity | 5.62 % | 48.70 % |
| Current Ratio | 0.98 X | 2.16 X |
| Book Value Per Share | 5.13 X | 1.93 K |
| Cash Flow From Operations | (49.06 M) | 971.22 M |
| Short Ratio | 7.79 X | 4.00 X |
| Earnings Per Share | (13.42) X | 3.12 X |
| Target Price | 34.38 | |
| Number Of Employees | 23 | 18.84 K |
| Beta | 0.86 | -0.15 |
| Market Capitalization | 289.54 M | 19.03 B |
| Total Asset | 150.73 M | 29.47 B |
| Retained Earnings | (370.26 M) | 9.33 B |
| Working Capital | 131.93 M | 1.48 B |
| Net Asset | 150.73 M |
Note: Acquisition by Jain Rita of 1043 shares of Avalo Therapeutics at 18.16 subject to Rule 16b-3 [view details]
Avalo Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Avalo . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 24445.88 | |||
| Daily Balance Of Power | (0.53) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 15.44 | |||
| Day Typical Price | 15.31 | |||
| Price Action Indicator | (0.66) | |||
| Period Momentum Indicator | (0.58) |
Avalo Therapeutics Target Price Consensus
Avalo target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Avalo Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Avalo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Avalo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Avalo Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAvalo Therapeutics Target Price Projection
Avalo Therapeutics' current and average target prices are 15.06 and 34.38, respectively. The current price of Avalo Therapeutics is the price at which Avalo Therapeutics is currently trading. On the other hand, Avalo Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Avalo Therapeutics Market Quote on 17th of January 2026
Target Price
Analyst Consensus On Avalo Therapeutics Target Price
Avalo Therapeutics Analyst Ratings
Avalo Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Avalo Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Avalo Therapeutics' financials, market performance, and future outlook by experienced professionals. Avalo Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Avalo Therapeutics Buy or Sell Advice
When is the right time to buy or sell Avalo Therapeutics? Buying financial instruments such as Avalo Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Avalo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Emerging Markets ETFs Thematic Idea Now
Emerging Markets ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Emerging Markets ETFs theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Avalo Stock Analysis
When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.